Description

Mazdutide 5mg × 10 vials

A synthetic dual GLP-1/glucagon receptor agonist studied for metabolic research, obesity-related models, appetite-regulation pathways, glucose metabolism, insulin-sensitivity mechanisms, liver-fat metabolism, energy expenditure, and broader metabolic-disease research protocols.

Product Overview

Compound: Mazdutide / IBI362
Strength: 5 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 5 mg
BAC water: 2 mL
Amount per unit: 25 mcg per unit

Research Dose

Protocol dependent.

Notes

Mazdutide, also known as IBI362, is described as an investigational dual agonist of the GLP-1 receptor and glucagon receptor. These receptor pathways are studied in relation to appetite regulation, glucose metabolism, insulin secretion, energy expenditure, liver-fat metabolism, and body-weight regulation.

Research literature has examined Mazdutide in obesity-related models, type 2 diabetes research, metabolic dysfunction-associated fatty liver disease pathways, insulin-sensitivity mechanisms, visceral-fat reduction, and broader metabolic-disease regulation.

Unlike GLP-1-only receptor agonists, Mazdutide is studied for combined GLP-1 and glucagon receptor activity, where GLP-1 pathways are associated with satiety and glucose regulation, while glucagon receptor activity is researched in relation to energy expenditure and hepatic fat metabolism.

Mazdutide remains an investigational compound in many jurisdictions. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.